^
Association details:
| Biomarker: | FCGR3A 158F |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Margenza (margetuximab-cmkb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
Published date:
09/07/2021
Excerpt:
OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm...
Secondary therapy:
Chemotherapy
Trial ID:
